{"id":"telmisartan-ramipril","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1017","moleculeType":"Small molecule","molecularWeight":"514.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Telmisartan is an angiotensin II receptor blocker (ARB) that directly antagonizes AT1 receptors, preventing vasoconstriction and aldosterone release. Ramipril is an ACE inhibitor that reduces angiotensin II production by blocking the conversion of angiotensin I. Together, they provide dual renin-angiotensin-aldosterone system (RAAS) inhibition for enhanced blood pressure reduction and cardiovascular protection.","oneSentence":"This combination blocks angiotensin II signaling through two complementary pathways: telmisartan blocks the angiotensin II type 1 receptor, while ramipril inhibits ACE to prevent angiotensin II formation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:37:54.180Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Cardiovascular risk reduction in hypertensive patients"}]},"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":"Sacubitril/Valsartan, Hypertension, Obesity","enrollment":180},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT00274599","phase":"PHASE4","title":"PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-10-09","conditions":"Hypertension","enrollment":812},{"nctId":"NCT04354350","phase":"","title":"Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-09-22","conditions":"Hypertension","enrollment":63744},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT00421863","phase":"PHASE4","title":"Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study","status":"COMPLETED","sponsor":"Heart Care Foundation","startDate":"2005-02","conditions":"Hypertension","enrollment":1111},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT00741585","phase":"PHASE4","title":"Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment","status":"COMPLETED","sponsor":"University of Vigo","startDate":"2008-09-01","conditions":"Essential Hypertension, Cardiovascular Disease, Stroke","enrollment":21983},{"nctId":"NCT00281593","phase":"PHASE3","title":"Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04","conditions":"Hypertension","enrollment":1354},{"nctId":"NCT01715584","phase":"PHASE4","title":"Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2012-07","conditions":"Hypertension","enrollment":80},{"nctId":"NCT00939588","phase":"PHASE2","title":"Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-07","conditions":"Hypertension","enrollment":88},{"nctId":"NCT00905528","phase":"","title":"TRENDY Follow-up: Study on Endothelial Function in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2002-01","conditions":"Type 2 Diabetes Mellitus","enrollment":69},{"nctId":"NCT02215005","phase":"PHASE1","title":"Steady State Pharmacokinetics of Telmisartan, Ramipril or the Combination Following Repeated Oral Doses to Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-06","conditions":"Healthy","enrollment":42},{"nctId":"NCT02214966","phase":"PHASE1","title":"Influence of Food on the Bioavailability of Telmisartan / Ramipril Fixed Dose Combination in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-10","conditions":"Healthy","enrollment":42},{"nctId":"NCT02214992","phase":"PHASE1","title":"Bioequivalence of Telmisartan/g Ramipril Fixed Dose Combination Compared With the Monocomponents Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-03","conditions":"Healthy","enrollment":84},{"nctId":"NCT02214979","phase":"PHASE1","title":"Bioequivalence of Telmisartan / Ramipril Fixed Dose Combination Compared With the Monocomponents Given Concomitantly to Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-03","conditions":"Healthy","enrollment":84},{"nctId":"NCT00153101","phase":"PHASE4","title":"Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-11","conditions":"Cardiovascular Diseases","enrollment":31546},{"nctId":"NCT00240422","phase":"PHASE4","title":"Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-02","conditions":"Diabetes Mellitus, Type 2, Hypertension","enrollment":96},{"nctId":"NCT00274612","phase":"PHASE4","title":"Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-10","conditions":"Hypertension","enrollment":801},{"nctId":"NCT00221845","phase":"PHASE3","title":"Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"1998-01","conditions":"Children, Chronic Renal Failure, Hypertension","enrollment":400},{"nctId":"NCT00738660","phase":"PHASE3","title":"Efficacy of Telmisartan and the Combination of Telmisartan and Ramipril in type1 Diabetes Patients With Nephropathy","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2007-02","conditions":"Diabetic Nephropathy","enrollment":30},{"nctId":"NCT00702936","phase":"PHASE4","title":"Telmisartan Versus Ramipril After Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Catholic University of the Sacred Heart","startDate":"2007-11","conditions":"Acute Coronary Syndrome, Myocardial Infarction, Coronary Disease","enrollment":50},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52},{"nctId":"NCT00208221","phase":"PHASE3","title":"Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes","status":"TERMINATED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2006-08","conditions":"Hypertension, Type 2 Diabetes, Albuminuria","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":36,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["cardace","cardiopri","tazloc"],"phase":"phase_3","status":"active","brandName":"Telmisartan, Ramipril","genericName":"Telmisartan, Ramipril","companyName":"Post Graduate Institute of Medical Education and Research, Chandigarh","companyId":"post-graduate-institute-of-medical-education-and-research-chandigarh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination blocks angiotensin II signaling through two complementary pathways: telmisartan blocks the angiotensin II type 1 receptor, while ramipril inhibits ACE to prevent angiotensin II formation. Used for Hypertension, Cardiovascular risk reduction in hypertensive patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}